港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

維立志博-B

85.850

-8.000-8.52%

成交量：193.06萬

成交額：1.70億

市值：170.84億

市盈率：-61.67

高：96.550

開：94.100

低：84.850

收：93.850

52周最高：97.500

52周最低：44.720

股本：1.99億

香港流通股本：1.53億

量比：1.74

換手率：1.26%

股息：- -

股息率：- -

每股收益(LYR):-1.392

淨資產收益率：-27.61%

總資產收益率：-9.92%

市淨率：11.73

市盈率(LYR):-61.67

市銷率: 83.77

資料載入中...

總覽公司新聞資訊公告

維立志博-B盤中異動下午盤快速下跌5.03%

維立志博-B(09887)：維利信™於複發性或轉移性三陰性乳腺癌IB/II期試驗的首例患者用藥

瞄準 PD-1 未竟需求，雙抗/TCE/ADC 三箭齊發引領腫瘤免疫新升級｜專訪維立志博創始人康小強博士

每日沽空追蹤 | 維立志博-B 02月06日沽空量成交2.17萬股，沽空比例為5.56%

每日沽空追蹤 | 維立志博-B 02月04日沽空量成交4.09萬股，沽空比例為7.35%

每日沽空追蹤 | 維立志博-B 02月03日沽空量成交5.19萬股，沽空比例為9.07%

維立志博－Ｂ(09887)股價上升8.13%，現價港幣$66.5

阿斯达克财经

維立志博生物科技發布2026年1月證券變動月報表

南京一藥企產品獲歐盟罕見病藥物資格認定

維立志博-B午後漲逾9% TCE雙抗LBL-034獲FDA快速通道資格認定

每日沽空追蹤 | 維立志博-B 01月29日沽空量成交3.33萬股，沽空比例為8.89%

港股異動 | 維立志博-B(09887)再漲近6% TCE雙抗LBL-034獲FDA快速通道資格認定

維立志博-B盤中異動早盤急速上漲5.13%報62.500港元

維立志博-B(09887)：LBL-034(GPRC5D/CD3雙特異性T-CELL ENGAGER，TCE)獲美國FDA授予快速通道資格認定

每日沽空追蹤 | 維立志博-B 01月27日沽空量成交3.65萬股，沽空比例為4.59%

華福證券：醫藥生物業新技術全面突破戰略看多中國創新出海

智通财经网

港股維立志博-B升逾5%

每日经济新闻

維立志博-B再升逾6% 維利信獲歐盟孤兒藥資格及美國FDA快速通道資格認定

港股異動 | 維立志博-B(09887)尾盤漲逾5% 雙特異性抗體維利信獲歐盟孤兒藥認定

維立志博-B01月23日主力淨流入526.9萬元散户資金拋售

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09887/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"維立志博-B","latestPrice":85.85,"timestamp":1776413294011,"preClose":93.85,"halted":0,"volume":1930608,"delay":0,"changeRate":-0.08524240809802877,"floatShares":153000000,"shares":199000000,"eps":-1.3921336071742132,"marketStatus":"休市中","change":-8,"latestTime":"04-17 16:08:14","open":94.1,"high":96.55,"low":84.85,"amount":169794050,"amplitude":0.124667,"askPrice":85.9,"askSize":2600,"bidPrice":85.8,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.354166326978553,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":93.85,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"volumeRatio":1.7439344646914776,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.392134,"volumeRatio":1.7439344646914776,"shares":199000000,"dividePrice":0,"high":96.55,"amplitude":0.124667,"preClose":93.85,"low":84.85,"week52Low":44.72,"pbRate":"11.73","psRate":"83.77","week52High":97.5,"institutionHeld":0,"latestPrice":85.85,"committee":-0.925926,"eps":-1.3921336071742132,"divideRate":0,"volume":1930608,"delay":0,"ttmEps":-1.354166326978553,"open":94.1,"prevYearClose":51,"prevWeekClose":92,"prevMonthClose":74,"prevQuarterClose":74,"fiveDayClose":92,"twentyDayClose":62.9,"sixtyDayClose":55.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762185600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-04-17","current":-63.396939,"percent":0.050562,"low":-76.458084,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"high":-30.202688,"avg":-40.496691,"sd":9.488441,"marketCap":16960268450},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450}],"updateTime":1776503538565},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610900729","title":"維立志博-B盤中異動 下午盤快速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610900729","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610900729?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 15:17","pubTimestamp":1770794242,"startTime":"0","endTime":"0","summary":"2026年02月11日下午盘15时17分，维立志博-B股票出现波动，股价快速跳水5.03%。截至发稿，该股报60.450港元/股，成交量29.03万股，换手率0.19%，振幅4.79%。维立志博-B股票所在的生物技术行业中，整体涨幅为0.60%。维立志博-B公司简介：我们是一家临床阶段生物科技公司,致力于创新疗法的发现、开发及商业化,以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021115172297a5beaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021115172297a5beaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","09887","BK1161","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610861798","title":"維立志博-B(09887)：維利信™於複發性或轉移性三陰性乳腺癌IB/II期試驗的首例患者用藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2610861798","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610861798?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 16:38","pubTimestamp":1770712703,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，评价维利信用于治疗复发性或转移性三阴性乳腺癌的Ib/II期临床研究首例患者已成功用药。该试验旨在评价奥帕替苏米单抗单独给药或联合白蛋白结合型紫杉醇治疗复发性或转移性三阴性乳腺癌患者的疗效及安全性。维利信亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。癌症是全球致病和致死的主要原因之一。在我国，乳腺癌每年新发病例数持续上升，估算达36万，死亡病例数达7.5万。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000500386.USD","BK1161","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609076519","title":"瞄準 PD-1 未竟需求，雙抗/TCE/ADC 三箭齊發引領腫瘤免疫新升級｜專訪維立志博創始人康小強博士","url":"https://stock-news.laohu8.com/highlight/detail?id=2609076519","media":"峰客访谈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609076519?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 16:31","pubTimestamp":1770366668,"startTime":"0","endTime":"0","summary":"超过 30 年创新药研发经验，其中 17 年以上抗体新药研发经验，领导多个抗癌抗体新药研发。临床数据显示，PD-1 对约 80% 的患者无效或最终耐药。根据目前已有的数据，LBL-024 在非小细胞肺癌、小细胞肺癌和肺外神经内分泌癌三个适应症的二期或注册性临床试验中展示出全球首创和同类最优潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206170038a483eb3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206170038a483eb3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609519077","title":"每日沽空追蹤 | 維立志博-B 02月06日沽空量成交2.17萬股，沽空比例為5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609519077","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609519077?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 16:30","pubTimestamp":1770366644,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月06日，跌2.49%，卖空量成交2.17万股，较上一交易日减少28.62%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163751a483d295&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163751a483d295&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609328338","title":"每日沽空追蹤 | 維立志博-B 02月04日沽空量成交4.09萬股，沽空比例為7.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609328338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609328338?lang=zh_tw&edition=fundamental","pubTime":"2026-02-04 16:30","pubTimestamp":1770193842,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月04日，跌1.44%，卖空量成交4.09万股，较上一交易日减少50.9%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163851a6d206ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163851a6d206ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608864423","title":"每日沽空追蹤 | 維立志博-B 02月03日沽空量成交5.19萬股，沽空比例為9.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608864423","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608864423?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 16:30","pubTimestamp":1770107441,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间02月03日，涨7.56%，卖空量成交5.19万股，较上一交易日减少27.62%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203163741a476c58d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203163741a476c58d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608401808","title":"維立志博－Ｂ(09887)股價上升8.13%，現價港幣$66.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2608401808","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608401808?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 15:08","pubTimestamp":1770102480,"startTime":"0","endTime":"0","summary":"[上升股]维立志博－Ｂ(09887) 股价在下午03:08比前收市价上升8.13%，现股价为港币$66.5。至目前为止，今日最高价为$66.5，而最低价为$61.5。总成交量为46.61万股，总成交金额为港币$2.986千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2602035261/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2602035261/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608386445","title":"維立志博生物科技發布2026年1月證券變動月報表","url":"https://stock-news.laohu8.com/highlight/detail?id=2608386445","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608386445?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 12:32","pubTimestamp":1770093155,"startTime":"0","endTime":"0","summary":"金吾财讯|南京维立志博生物科技股份有限公司于2026年2月3日向香港交易及结算所有限公司提交了2026年1月的证券变动月报表。该月报表显示，公司在2026年1月的法定/注册股本及已发行股份均未发生变动。维立志博生物科技表示，将继续严格遵守相关法律法规，确保公司股份的稳定与合规运营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203124526a475f1e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203124526a475f1e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608671006","title":"南京一藥企產品獲歐盟罕見病藥物資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2608671006","media":"金台资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608671006?lang=zh_tw&edition=fundamental","pubTime":"2026-02-01 11:39","pubTimestamp":1769917156,"startTime":"0","endTime":"0","summary":"近日，南京江北新区生物医药谷企业维立志博宣布，其核心产品维利信已获欧盟委员会授予的罕见病药物资格认定，用于治疗肺外神经内分泌癌。罕见病药物，又称孤儿药。根据欧盟委员会的定义，孤儿药是指用于诊断、预防或治疗有生命危险或导致慢性衰弱疾病的药物，并且患者比例不超过欧盟人口总数的万分之五。维立志博首席医学官蔡胜利表示，本次获得欧盟孤儿药资格认定，标志着国际监管机构对公司技术平台及临床数据的再次认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260201114230a46e4777&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260201114230a46e4777&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607809556","title":"維立志博-B午後漲逾9% TCE雙抗LBL-034獲FDA快速通道資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2607809556","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607809556?lang=zh_tw&edition=fundamental","pubTime":"2026-01-30 14:14","pubTimestamp":1769753640,"startTime":"0","endTime":"0","summary":"　　维立志博-B午后股价上涨8.78%，现报65.65港元，成交额5281.46万港元。　　维立志博宣布，1月27日，公司基于TCE技术平台LeadsBody自主研发的具有独特2：1结构和条件性激活的GPRC5D/CD3双特异性抗体LBL-034获得美国食品药品监督管理局授予快速通道资格认定，用于治疗复发/难治性多发性骨髓瘤。　　华福证券发布研报称，维立志博基于激动剂平台+TCE平台+ADC，全面布局下一代肿瘤免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-30/doc-inhkakfh0203738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000252160.HKD","09887","HK0000500386.USD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607056346","title":"每日沽空追蹤 | 維立志博-B 01月29日沽空量成交3.33萬股，沽空比例為8.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607056346","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607056346?lang=zh_tw&edition=fundamental","pubTime":"2026-01-29 16:30","pubTimestamp":1769675444,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间01月29日，涨1.51%，卖空量成交3.33万股，较上一交易日减少5.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129164306a463ee94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129164306a463ee94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000252160.HKD","09887","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607777506","title":"港股異動 | 維立志博-B(09887)再漲近6% TCE雙抗LBL-034獲FDA快速通道資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2607777506","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607777506?lang=zh_tw&edition=fundamental","pubTime":"2026-01-29 10:59","pubTimestamp":1769655560,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B(09887)再涨近6%，截至发稿，涨4.63%，报62.2港元，成交额1142.28万港元。消息面上，维立志博宣布，公司基于专有TCE技术平台LeadsBody自主研发的GPRC5D/CD3双特异性抗体LBL-034，获得美国食品药品监督管理局（FDA）授予的快速通道资格认定，用于治疗复发/难治性多发性骨髓瘤（RRMM）。这是继2024年10月获FDA孤儿药认定后，该产品在国际化开发道路上的又一重要里程碑，标志着其临床价值与开发策略进一步获得国际监管机构的认可。据悉，LBL-034是一款靶向GPRC5D及CD3的人源化双特异性T细胞衔接器。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","HK0000252160.HKD","HK0000500386.USD","BK4588","09887","VT","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607056391","title":"維立志博-B盤中異動 早盤急速上漲5.13%報62.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607056391","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607056391?lang=zh_tw&edition=fundamental","pubTime":"2026-01-29 10:21","pubTimestamp":1769653277,"startTime":"0","endTime":"0","summary":"2026年01月29日早盘10时21分，维立志博-B股票出现波动，股价急速上涨5.13%。截至发稿，该股报62.500港元/股，成交量11.12万股，换手率0.07%，振幅6.31%。资金方面，该股资金流入448.004万港元，流出158.687万港元。维立志博-B股票所在的生物技术行业中，整体跌幅为1.73%。其相关个股中，银诺医药-B、维立志博-B、创胜集团-B涨幅较大，振幅较大的相关个股有银诺医药-B、中生北控生物科技、MIRXES-B，振幅分别为18.28%、15.53%、13.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012910211797a3e121&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012910211797a3e121&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606754444","title":"維立志博-B(09887)：LBL-034(GPRC5D/CD3雙特異性T-CELL ENGAGER，TCE)獲美國FDA授予快速通道資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2606754444","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606754444?lang=zh_tw&edition=fundamental","pubTime":"2026-01-28 08:38","pubTimestamp":1769560721,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2026年1月27日，LBL-034(GPRC5D/CD3双特异性抗体)获美国食品药品监督管理局(“FDA”)授予快速通道资格认定(“FTD”)，用于治疗复发╱难治性多发性骨髓瘤(“RRMM”)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1398303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B(09887)：LBL-034(GPRC5D/CD3双特异性T-CELL ENGAGER，TCE)获美国FDA授予快速通道资格认定","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK1161","09887","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606748735","title":"每日沽空追蹤 | 維立志博-B 01月27日沽空量成交3.65萬股，沽空比例為4.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606748735","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606748735?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 16:30","pubTimestamp":1769502645,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间01月27日，涨3.89%，卖空量成交3.65万股，较上一交易日增加60.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127164320a6b23a9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127164320a6b23a9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606272282","title":"華福證券：醫藥生物業新技術全面突破 戰略看多中國創新出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2606272282","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606272282?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 11:01","pubTimestamp":1769482871,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华福证券发布研报称，2025年中国创新药全球竞争力凸显，出海交易创新高，多家企业扭亏为盈。战略看多中国创新出海。华福证券主要观点如下：国内复盘：全球竞争力凸显，企业扭亏为盈+管线出海价值新高度2025创新药指数大涨，Biopharma和Biotech持仓比例显著提升，核心驱动因素是中国创新药全球竞争力凸显。创新药市场份额快速提升，肿瘤与免疫领域创新药份额超32%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127110355a6b10694&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127110355a6b10694&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","02162","09606","06978","HK0000165453.HKD","BK1593","BK1161","06938","02615","02157","06955","BK1574","01093","01530","09926","01801","02096","09887","BK1583","06160","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606276635","title":"港股維立志博-B升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606276635","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606276635?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 10:18","pubTimestamp":1769480299,"startTime":"0","endTime":"0","summary":"每经AI快讯，维立志博-B(09887.HK)涨超5%，截至发稿涨5.07%，报62.2港元，成交额2440.12万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273631843738.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273631843738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606373574","title":"維立志博-B再升逾6% 維利信獲歐盟孤兒藥資格及美國FDA快速通道資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2606373574","media":"智通财经","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606373574?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 10:15","pubTimestamp":1769480134,"startTime":"0","endTime":"0","summary":"维立志博-B再涨超6%，截至发稿，涨5.07%，报62.2港元，成交额2440.12万港元。消息面上，维立志博1月22日宣布，核心产品维利信获欧盟委员会授予的孤儿药资格认定，用于治疗肺外神经内分泌癌。值得注意的是，1月14日，维利信获美国FDA授予快速通道资格认定，用于治疗肺外神经内分泌癌。维利信是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127103255a6b0e6f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127103255a6b0e6f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606329296","title":"港股異動 | 維立志博-B(09887)尾盤漲逾5% 雙特異性抗體維利信獲歐盟孤兒藥認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2606329296","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606329296?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 15:29","pubTimestamp":1769412554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B早盘重挫后逐步转涨，尾盘涨幅扩大逾5%。截至发稿，涨5%，报58.85港元，成交额4573.08万港元。消息面上，维立志博宣布，核心产品维利信获欧盟委员会授予的孤儿药资格认定，用于治疗肺外神经内分泌癌。维利信是一种同时靶向PD-L1与4-1BB的抗体，已在中国的两项临床试验中显示出良好的疗效信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","FSXEmain","FESXmain","BK1161","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605404295","title":"維立志博-B01月23日主力淨流入526.9萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2605404295","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605404295?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 16:15","pubTimestamp":1769156123,"startTime":"0","endTime":"0","summary":"01月23日, 维立志博-B股价涨6.56%，报收56.05元，成交金额3214.1万元，换手率0.38%，振幅7.13%，量比2.34。维立志博-B今日主力资金净流入526.9万元，上一交易日主力净流出0万元。该股近5个交易日下跌0.80%，主力资金累计净流出610.1万元；近20日主力资金累计净流入642.4万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123161702a6a43130&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123161702a6a43130&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09887","HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":158,"code":"91000000","status":"200"}]}}